GYNECOLOGICAL ENDOCRINOLOGY is a prestigious open-access journal published by Taylor & Francis Ltd, focusing on the dynamic fields of endocrinology, obstetrics, and gynecology. With its ISSN of 0951-3590 and E-ISSN of 1473-0766, this journal provides a vital platform for the dissemination of high-quality research and advancements in gynecological endocrinology since its inception in 1987. Notably, it attained an Open Access status in 2023, enhancing its reach and accessibility to researchers and practitioners worldwide. The journal is renowned for its rigorous peer-review process and holds significant standing with a Q2 ranking in Obstetrics and Gynecology and a Q3 ranking in Endocrinology, Diabetes, and Metabolism, as of 2023. It is indexed with commendable Scopus ranks in various medical domains, offering a reliable resource for current methodologies and future directions in gynecological health. With the growing emphasis on women's health and endocrinological research, GYNECOLOGICAL ENDOCRINOLOGY serves as an essential repository for innovative studies, clinical insights, and emerging therapeutic strategies, making it an invaluable resource for researchers, clinicians, and students alike.

Basic and Clinical Andrology, published by BMC, is a leading open access journal dedicated to the advancement of knowledge in the field of reproductive medicine and urology. Since its launch in 2013, the journal has aimed to provide a platform for the dissemination of high-quality research, bridging the gap between basic science and clinical practice. With an impressive reputation evidenced by its Q2 ranking in both reproductive medicine and urology, it serves as a vital resource for researchers, healthcare professionals, and students looking to stay updated on the latest developments in andrology. The journal actively encourages submissions across a diverse range of topics, contributing to our understanding of male reproductive health issues, advancements in treatment protocols, and innovative therapeutic approaches. Located in the United Kingdom, Basic and Clinical Andrology plays a critical role in the global discourse on andrology, offering researchers an opportunity to share their findings with a broad audience committed to improving health outcomes in these crucial fields.

Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

The Journal of Egyptian Women's Dermatological Society, published by Wolters Kluwer Medknow Publications, is an essential platform dedicated to advancing the field of dermatology through a valuable focus on women's health issues. Established to provide an open access outlet since 2019, this journal aims to disseminate research, case studies, and reviews that address the unique dermatological needs and concerns of women, particularly in the Egyptian context. Despite its current ranking in the Q4 category in dermatology and a Scopus rank of #117 out of 142 with a 17th percentile, the journal serves a critical role in fostering scholarly communication among researchers, clinicians, and academicians. With a commitment to promoting knowledge advancement and community engagement, this journal invites submissions that align with its objectives, specifically geared towards empirical research and innovative practices in dermatology impacting women's health.

Multiple Sclerosis Journal-Experimental Translational and Clinical, published by SAGE Publications, Inc., is an essential open-access platform since 2015 dedicated to advancing research in the field of multiple sclerosis and related neurological disorders. With an ISSN of N/A and an E-ISSN of 2055-2173, the journal aims to bridge the gap between experimental studies and clinical applications, offering valuable insights into cellular and molecular neuroscience as well as clinical neurology. The journal holds a reputable Q3 ranking in Cellular and Molecular Neuroscience and a Q2 ranking in Neurology (Clinical) for 2023, indicating its significant contribution to these fields. Positioned at the intersection of scientific discovery and clinical practice, the Multiple Sclerosis Journal serves as an indispensable resource for researchers, clinicians, and students dedicated to improving outcomes for individuals affected by multiple sclerosis and related disorders. With a Scopus ranking of #163/400 in Medicine - Neurology and #67/97 in Neuroscience, this journal continues to play a pivotal role in shaping the future of neurological research and therapy.

HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.

JAMA Oncology, published by the American Medical Association, stands at the forefront of cancer research as a premier peer-reviewed journal in the field. With an ISSN of 2374-2437 and an impressive impact factor reflecting its critical insights, the journal has achieved a top-tier position, being ranked in the Q1 quartile for both Cancer Research and Oncology as of 2023, and demonstrating exceptional performance in Medicine as well. Spanning a converged publication period from 2015 through 2024, JAMA Oncology publishes cutting-edge research, clinical trials, and reviews that are pivotal in advancing our understanding and treatment of cancer. The journal's Scopus ranks highlight its global impact, placing it in the top deciles within its categories, ensuring that it remains a vital resource for oncologists, researchers, and students alike. While it currently does not offer open access, JAMA Oncology continues to provide invaluable contributions to the scientific community, promoting a deeper understanding of oncological challenges and breakthroughs.

CLINICAL OBSTETRICS AND GYNECOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, stands as a pivotal journal in the field of obstetrics and gynecology, boasting a rich history since its inception in 1958. With its ISSN 0009-9201 and E-ISSN 1532-5520, the journal serves as a critical repository of contemporary research and clinical advancements, providing invaluable insights to healthcare professionals and researchers. As a prominent Q2 ranked journal in the Obstetrics and Gynecology category, it is recognized for its impactful contributions to medical practice and education, holding a respectable Scopus rank of #103 out of 209, placing it in the 50th percentile. While not an open-access journal, it ensures wide dissemination of knowledge through institutional subscriptions, enhancing the accessibility of its peer-reviewed content. The scope of the journal encompasses a diverse range of topics vital to the ongoing evolution of women's health, making it an essential resource for those dedicated to fostering clinical excellence and advancing research in obstetrics and gynecology.

The International Journal of Reproductive Biomedicine, an esteemed publication by SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES, serves as a pivotal platform in the fields of obstetrics and gynecology as well as reproductive medicine. Established in 2011 and transitioning to an open access model in 2015, this journal facilitates the dissemination of innovative research and critical findings to a global audience, particularly focusing on advancements in reproductive health and biomedicine. With an impact factor reflective of its commitment to high-quality scientific inquiry, the journal has achieved a notable ranking of Q3 in both its categories for 2023, contributing to its growing influence within the academic community. Researchers and professionals benefit from its broad scope, which encompasses a range of topics essential to reproductive health, thus fostering a rich exchange of knowledge. The journal's accessibility allows students and professionals alike to engage with the latest findings and contribute to ongoing discussions within this vital field of study.

Gynecologic Oncology Reports is a pivotal interdisciplinary journal published by Elsevier Science Inc. that has been dedicated to advancing the understanding of women's health since its inception in 2014. This Open Access journal, available to a global audience, facilitates the dissemination of high-quality research in the fields of gynecology and oncology, allowing for the free exchange of knowledge and fostering collaboration among researchers, clinicians, and students. With an impact factor reflective of its commitment to clinical relevance, Gynecologic Oncology Reports holds a Q3 ranking in both obstetrics and gynecology as well as oncology categories, contributing to its visibility and the prestige of published work. Situated in the Netherlands and operating within an open-access framework, it ensures that critical findings and advancements reach a broad readership. The journal serves as a vital resource for those aiming to stay at the forefront of gynecologic oncology, promoting improved patient outcomes through cutting-edge research. As it converges towards its 10th anniversary in 2024, Gynecologic Oncology Reports continues to be an essential platform for scholarly communication in this important field.